His previous board experience includes Aurinia Pharmaceuticals, Exicure (chairman), Assertio (chairman), Raptor Pharmaceutical Corp., XOMA Corporation, and Sucampo Pharmaceuticals. Mr. Walbert is also ...

Aurinia Pharmaceuticals (AUPH) has released an update.Don't Miss our Black Friday Offers:Discover the latest stocks recommended by top Wall ...

New Guidelines Presented at ACR Convergence 2024 Recommend First-Line Therapy with LUPKYNIS ® (voclosporin) as Part of a Triple Immunosuppressive LN Treatment Regimen. ROCKVILLE, ...

The sFlt-1/PlGF ratio did not effectively gauge future preeclampsia risk in pregnant patients with SLE and proteinuria.

GSA Capital Partners LLP cut its position in shares of Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH – Free Report) (TSE:AUP) by 44.9% during the third quarter, according to the company in its most recent ...

Aurinia Pharmaceuticals (AUPH) has released an update. Aurinia Pharmaceuticals has unveiled new data underscoring the importance of early ...

Aurinia Pharmaceuticals Reports Q3 and Nine Months 2024 Financial and Operational Results, Announces Strategic Restructuring to Sharpen Focus on Continued LUPKYNIS® Growth and AUR200 Development ...

Aurinia Pharmaceuticals Inc. announced that it has appointed Craig Johnson to its Board of Directors (the Board) to support ...

Aurinia Pharmaceuticals (Nasdaq: AUPH) has announced a major strategic overhaul, reducing its workforce by almost half to focus on driving Lupkynis (voclosporin) growth. The changes, which will also ...

Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Q3 2024 Earnings Call Transcript November 7, 2024 Aurinia Pharmaceuticals Inc.

Aurinia Pharmaceuticals Inc. had a solid Q3 and announced cost cuts, sparking rumors of potential acquisition and continued ...

Aurinia has announced a 45% workforce reduction to bolster sales of the lupus drug Lupkynis and advance the development of ...